CompletedNCT04053699
Bleeding Incidence in VWD Patients Undergoing On-Demand Treatment
Studying Von Willebrand disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Octapharma
- Principal Investigator
- Cristina Solomon, MDOctapharma
- Intervention
- Von Willebrand Factor-Containing Product(drug)
- Enrollment
- 56 target
- Eligibility
- All sexes
- Timeline
- 2019 – 2021
Study locations (15)
- Children's Healthcare of Atlanta, Atlanta, Georgia, United States
- Republican Research Center for Radiation Medicine and Human Ecology, Homyel, Belarus
- Specialized Hospital for Active Treatment of Haematological Diseases" EAD, Sofia, Sofia, Bulgaria
- "UMHAT Sveta Marina" EAD., Varna, Bulgaria
- University Hospital Centre Zagreb, Zagreb, Croatia
- Medical Centre Hungarian Defence Forces, Budapest, Hungary
- Debreceni Egyetem Klinikai Központ, Regionális Haemophilia és Thrombophilia Központ, Debrecen, Hungary
- University Clinical Center, Department of Internal Medicine, Hematology, Pécs, Hungary
- Hotel Dieu de France Hospital, Beirut, Lebanon
- American University of Beirut Medical Center, Beirut, Lebanon
- Nini Hospital, Tripoli, Lebanon
- Federal State Budgetary Scientific Institution Kirov Scientific-Research Institute of Hematology and Blood Transfusion of Federal, Kirov, Russia
- Morosovskaya Children Clinical Hospital, Moscow Health Department, Department of General Hematology with the Pathology of Hemostasis, Moscow, Russia
- State Institution "National Children's Specialized Hospital "OKHMATDYT" of the Ministry of Health of Ukraine," Center of Hemostasis Pathology, Kyiv, Ukraine
- Community Institution of Lviv Oblast Council "West-Ukrainian Specialized Children's Medical Center, Lviv, Ukraine
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04053699 on ClinicalTrials.govOther trials for Von Willebrand disease
Additional recruiting or active studies for the same condition.
- RECRUITINGNCT07404644An Observational Study of Vonicog Alfa (rVWF) in Pediatric Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT07115004Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)Vega Therapeutics, Inc
- RECRUITINGPHASE3NCT07129343A Study of Recombinant Von Willebrand Factor (rVWF) in Chinese Participants With Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06998524A Study to Assess the Efficacy and Safety of Emicizumab in Participants With Type 3 Von Willebrand DiseaseHoffmann-La Roche
- RECRUITINGNCT06883240An Observational Study of Participants With Type 3 Von Willebrand Disease on Prophylactic Standard-of-Care TreatmentHoffmann-La Roche
- RECRUITINGPHASE3NCT05582993A Study of Vonicog Alfa (rVWF) in Children With Severe Von Willebrand Disease (vWD)Takeda
- RECRUITINGPHASE3NCT06205095A Pilot Crossover Trial of Prophylactic Wilate Compared to Placebo for Heavy Menstrual Bleeding in Patients with VWDUnity Health Toronto
- RECRUITINGPHASE1, PHASE2NCT05776069Study of VGA039 in Healthy Volunteers and Patients With Von Willebrand Disease (VIVID)Vega Therapeutics, Inc